Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Open-label, Multicenter, National, Non-interventional Phase IV Trial of the Effectiveness, Safety and Tolerability of Tarceva as Second-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC), After Failure of First-line Treatment With a Pemetrexed-containing Chemotherapy Regimen

NCT01664533 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01664533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01664533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Open-label, Multicenter, National, Non-interventional Phase IV Trial of the Effectiveness, Safety and Tolerability of Tarceva as Second-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC), After Failure of First-line Treatment With a Pemetrexed-containing Chemotherapy Regimen
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
September 30, 2011
Completion date
August 31, 2013
Enrollment
57 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer